<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS: Epstein-Barr virus (EBV) immortalises B cells in vitro and is associated with several <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Most phenotypic effects of EBV are mediated by latent membrane protein 1 (LMP1), which interacts with <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor receptor associated factors (TRAFs) to activate NF-kappaB </plain></SENT>
<SENT sid="2" pm="."><plain>This study examines TRAF1 and LMP1 expression in EBV associated lymphoproliferations </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: TRAF1 expression was investigated in 26 Hodgkin <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (<z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e>; 18 EBV+, eight EBV-), seven EBV+ Burkitt <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>), two <z:e sem="disease" ids="C0021345" disease_type="Disease or Syndrome" abbrv="">infectious mononucleosis</z:e> (IM) tonsils, and lymphoreticular tissue from eight <z:hpo ids='HP_0011010'>chronic</z:hpo> virus carriers </plain></SENT>
<SENT sid="4" pm="."><plain>Seven anaplastic large cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> and 10 follicular B cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> were also studied </plain></SENT>
<SENT sid="5" pm="."><plain>Colocalisation of TRAF1 and LMP1 was studied by immunofluorescent double labelling and confocal laser microscopy </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: TRAF1 colocalises with LMP1 in EBV infected cells in IM </plain></SENT>
<SENT sid="7" pm="."><plain>EBV positive lymphocytes from <z:hpo ids='HP_0011010'>chronic</z:hpo> virus carriers were negative for TRAF1 and LMP1 </plain></SENT>
<SENT sid="8" pm="."><plain>In <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e> biopsies, TRAF1 was strongly expressed independently of EBV status, whereas <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cases were TRAF1- </plain></SENT>
<SENT sid="9" pm="."><plain>In EBV+ <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e> cases, TRAF1 colocalised with LMP1 </plain></SENT>
<SENT sid="10" pm="."><plain>Eight of 10 follicular <z:hpo ids='HP_0002665'>lymphomas</z:hpo> expressed TRAF1 in centroblast-like cells </plain></SENT>
<SENT sid="11" pm="."><plain>Four of seven anaplastic large cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> weakly expressed TRAF1 </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSIONS: These results suggest that in non-neoplastic lymphocytes, TRAF1 expression is dependent on the presence of LMP1, and that in IM B cells in vivo, LMP1 associated signalling pathways are active </plain></SENT>
<SENT sid="13" pm="."><plain>In <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e>, TRAF1 is expressed independently of EBV status, probably because of constitutive NF-kappaB activation </plain></SENT>
<SENT sid="14" pm="."><plain>The function of TRAF1 in <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e> remains to be determined </plain></SENT>
</text></document>